Intravitreal faricimab for diabetic macular oedema and neovascular age-related macular degeneration: general considerations and practical recommendations by an expert panel of Italian retina specialists.

چکیده

Faricimab, a bispecific antibody targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), introduces a novel therapeutic option for diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD). This consensus document, developed by an expert panel…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• رتینوپاتی دیابتی
• درمان های ضد VEGF